Core Insights - Aclarion, Inc. presented findings on Modic changes (MC) and chronic low back pain (cLBP) at the 50th International Society for the Study of the Lumbar Spine Annual Meeting 2024, highlighting the use of their Nociscan solution to better understand MC in cLBP patients [1][2][3] Company Overview - Aclarion is a healthcare technology company focused on chronic low back pain, utilizing Magnetic Resonance Spectroscopy (MRS) and proprietary algorithms to help physicians identify painful versus nonpainful discs in the lumbar spine [5][6] - The Nociscan platform is the first evidence-supported SaaS solution that noninvasively quantifies chemical biomarkers associated with disc pain, providing critical insights for treatment optimization [2][5][6] Research Findings - A prospective study involving 88 patients with low back pain for over three months was conducted, measuring intradiscal propionic acid (PA) levels to understand the etiology of MC and its association with treatment responses [1][2] - The study challenges the notion of a sterile disc environment and suggests that PA levels could help stratify patients for personalized treatment approaches [2][3] Industry Context - Globally, 266 million people suffer from spinal degeneration and low back pain, with Modic changes and vertebral endplate irregularities being significant areas of research [3] - Current diagnostic methods lack noninvasive techniques for identifying disc infections, making the measurement of PA via Nociscan a potential breakthrough for personalized treatment strategies [3]
Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes